“The development of Muse, a result of our ongoing collaboration with OpenAI and Formation Bio, represents another proof point ...

From the company's own site, we can see this pharma brand has a diversified portfolio of therapies across multiple clinical ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

I-Mab, a U.S.-based biotech firm, reported promising financial and clinical advancements in its third-quarter 2024 results. The company is set to initiate a Phase 2 study for uliledlimab in lung ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

The emergence of regulatory concerns over the sale have hit Sanofi shares this week, and the company will be under pressure to communicate a clear plan when it reports third quarter earnings next ...

The firm owned 44,289 shares of the company’s stock after acquiring an additional 8,494 shares during the quarter. Crossmark ...

Oct 25 (Reuters) - French drug maker Sanofi (SASY.PA), opens new tab on ... estimate of 4 billion euros in a poll posted on the company's website. Vaccines sales rose a currency-adjusted 25.5 ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...